Pfizer Ltd.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company's performance and outlook.

Pfizer Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a strong one-year return outperforming the Sensex, recent price action and technical parameters suggest caution for investors as the stock faces downward pressure in the near term.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. witnessed a sharp gap down at the opening bell on 2 Mar 2026, declining by 5.11% to an intraday low of Rs 4,809.3, reflecting heightened market concerns and a continuation of recent downward momentum. The stock underperformed its sector and the broader market, marking a weak start to the trading session.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. demonstrated a strong intraday performance on 10 Feb 2026, surging to an intraday high of Rs 5,150, marking an 8.18% increase from its previous close. The pharmaceutical giant outpaced the broader market and its sector peers, reflecting heightened trading activity and volatility throughout the session.

Pfizer Ltd., one of India's leading pharmaceutical companies with a market capitalisation of ₹21,203 crores, reported mixed results for Q2 FY26 (Jul-Sep'25), with net profit declining 1.42% quarter-on-quarter to ₹189.02 crores despite revenue growth of 6.52%. The stock rallied 3.93% on February 9, 2026, trading at ₹4,775, though it remains down 20.25% from its 52-week high of ₹5,987.65, reflecting investor concerns about premium valuations and decelerating growth momentum.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with the latest insights into its performance and outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite a modest day gain of 0.92%, the stock’s technical indicators reveal a complex picture, with several metrics signalling caution for investors as the company’s mojo grade was downgraded from Hold to Sell on 29 December 2025.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock's medium to long-term outlook.

Pfizer Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 29 Dec 2025. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, and subdued long-term growth prospects despite recent positive quarterly financial results.